Semaglutide: A Comprehensive Review of Its Mechanisms, Clinical Effectiveness, and Future Prospects in Metabolic Therapy

Semaglutide, a weekly glucagon-like peptide-1 receptor agonist, has emerged as a significant advancement in treating the pathophysiological processes associated with metabolic dysregulation. It works by targeting GLP-1 receptors.

Obesity and type 2 diabetes are prevalent global health issues, affecting over 800 million and 537 million individuals, respectively. These conditions are linked to metabolic dysregulation.

Clinical studies demonstrate that semaglutide effectively sustains glycemic control, promotes substantial weight loss, and offers cardiovascular and renal protective benefits. It has also received FDA clearance for metabolic dysfunction-associated steatohepatitis (MASH).

The primary tolerability concern with semaglutide is gastrointestinal side effects. However, its overall risk-benefit profile indicates its growing importance in metabolic therapy.

Pharmacogenomic insights are being explored for personalized semaglutide therapy, though clinical applications are still experimental. Future priorities include developing refined combination medicines, advancing precision medicine, and addressing healthcare inequities to enhance population-level outcomes, despite current challenges in global accessibility.